Post Traumatic Stress Disorder: Clinical Trials

18 completed, 16 recruiting, 6 terminated, 5 suspended. 57 Phase 2, 6 Phase 1, 5 Phase 3.

By phase and status

Phase	Trials	Status
Phase 2	57	Completed 18, Recruiting 16, Terminated 6, Suspended 5, Unknown 5, Not yet recruiting 3, Active not recruiting 2, Withdrawn 2
Phase 1	6	Completed 3, Not yet recruiting 1, Recruiting 1, Terminated 1
Phase 3	5	Recruiting 3, Completed 1, Unknown 1

Follow Post Traumatic Stress Disorder: new trials by email Literature Review of Post Traumatic Stress Disorder trials Research Report on Post Traumatic Stress Disorder

Trials (filtered) newest first · largest first

All 57 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Department of Defense PTSD Adaptive Platform Trial - Intervention D - SLS-002 Intervention D SLS-002, Intervention D Placebo - Post Traumatic Stress Disorder	Phase 2	Suspended	Global Coalition for Adaptive Research	200	2028-05-01	2026-05-20
Department of Defense PTSD Adaptive Platform Trial - Intervention B - Vilazodone Intervention B Vilazodone Hydrochloride (HCl), Intervention B Placebo - Post Traumatic Stress Disorder	Phase 2	Not yet recruiting	Global Coalition for Adaptive Research	200	2027-08-01	2026-05-20
Clinical Trial of MDMA-Assisted Therapy for Military Service Members With Posttraumatic Stress Disorder TREATMENT ARM: Full dose, CONTROL ARM: Active-controlled - PTSD, Post Traumatic Stress Disorder PTSD	Phase 2	Not yet recruiting	U.S. Army Medical Research and Development Command	86	2026-10-01	2026-07-15
Mindfulness-based Psilocybin Therapy for PTSD Psilocybin + MBCT therapy, Active Comparator: Psilocybin with Support Only - Post Traumatic Stress Disorder, Depression - Major Depressive Disorder	Phase 2	Recruiting	Anthony P King	30	2026-09-01	2026-10-19
Wayne State Warriors Marijuana Clinical Research Program: Cannabinoid Adjunct to Prolonged Exposure & Recovery Cannabidiol (CBD) only, Placebo only, Delta-9-tetrahydrocannabinol (THC) only - PTSD, Post Traumatic Stress Disorder	Phase 1 / Phase 2	Not yet recruiting	Leslie Lundahl	280	2026-09-01	2026-08-26
MDMA-Assisted Massed Exposure Therapy for PTSD 3,4-Methylenedioxymethamphetamine (MDMA), Placebo, Massed Prolonged Exposure (PE) - Post Traumatic Stress Disorder	Phase 2	Recruiting	Emory University	200	2026-07-01	2026-05-26
MDMA Therapy in Veterans With PTSD MDMA - Post Traumatic Stress Disorder	Phase 2	Recruiting	Sunstone Medical	52	2026-06-30	2026-07-01
Psilocybin-Assisted Cognitive Processing Therapy for Chronic PTSD Psilocybin - Post Traumatic Stress Disorder, PTSD	Phase 2	Active not recruiting	Unity Health Toronto	15	2026-06-01	2026-10-06
Psilocybin-Assisted Therapy for Sexual Assault-Related PTSD Psilocybin 25 mg - Post Traumatic Stress Disorder, PTSD	Phase 2	Recruiting	Sunstone Medical	70	2026-05-23	2026-07-01
MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use Disorder Full Dose MDMA, MDMA-Assisted psychotherapy, Active Placebo Dose MDMA - Post Traumatic Stress Disorder, Alcohol Use Disorder	Phase 2 / Phase 3	Recruiting	VA Office of Research and Development	80	2026-05-18	2026-06-02
Determining the Potential for Efficacy of OTX-601 in Reducing PTSD Symptoms OTX-601 Digital Therapeutic, OTX-003 Comparator app - PTSD, Post Traumatic Stress Disorder	Phase 2	Active not recruiting	Oui Therapeutics, Inc.	40	2025-12-09	2026-07-15
Warrior CARE: Cannabis Behavioral Health Tetrahydrocannabinol, Cannabidiol, Placebo - Post Traumatic Stress Disorder, Cannabis Use	Phase 1 / Phase 2	Recruiting	Wayne State University	500	2025-09-22	2026-08-07
Randomized Controlled Trial of Treatment to Optimize Heart Rate Variability for Persistent Post-Concussion Symptoms HRV Coherence Ratio, NSI, Pittsburgh Sleep Quality Index (PSQI) - Autonomic Nervous System Disease, Concussive Injury	Phase 2 / Phase 3	Recruiting	Virginia Commonwealth University	148	2025-09-02	2026-09-22
Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD. Experiment 1: Three-day aversive conditioning, extinction, and extinction retention testing paradigm, Allopregnanolone (Allo) with 6% USP Dexolve (sulfobutyl ether-beta-cyclodextrin sodium salt) in 0.9% saline for IV infusion will be provided by the University of California, Davis, GMP manufacturer., Experiment 1. Three-day aversive conditioning, extinction, and extinction retention testing paradigm - Post Traumatic Stress Disorder	Phase 2	Recruiting	Massachusetts General Hospital	96	2025-08-04	2025-11-05
MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress Disorder 3,4-methylenedioxymethamphetamine, d-amphetamine, Therapy - Post Traumatic Stress Disorder	Phase 2	Recruiting	Stephen Robert Marder	40	2025-03-01	2026-08-19
MDMA-Assisted CBCT for PTSD vs CBCT RCT MDMA assisted psychotherapy, Psychotherapy - Post Traumatic Stress Disorder	Phase 2	Recruiting	Remedy	60	2024-11-15	2026-08-19
Efficacy of Traumatic Memory Modification Using Memory Reconsolidation and Propranolol Among Adolescents With PTSD Propranolol, Placebo - Post Traumatic Stress Disorder	Phase 2	Withdrawn	Rennes University Hospital		2024-10-01	2025-09-08
Enhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33) COGENT, Sham Program - Anxiety Disorders, Depression	Phase 2 / Phase 3	Recruiting	University of California, San Diego	128	2024-10-01	2025-10-24
An Evaluation of the Safety and Efficacy of Methylone for the Treatment of PTSD Methylone - Post Traumatic Stress Disorder	Phase 2	Completed	Transcend Therapeutics	62	2024-04-04	2026-10-30
An Evaluation of the Long-term Efficacy and Safety of Methylone for the Treatment of PTSD Methylone - Post Traumatic Stress Disorder	Phase 2	Completed	Transcend Therapeutics	44	2024-03-06	2025-11-25

Showing 20 of 57. Sign in to see all of them.

Narrower conditions

Stress Disorders, Post-Traumatic (57)  ·  Alcoholism (6)  ·  Depression (3)  ·  Suicide (3)  ·  Trauma and Stressor Related Disorders (3)  ·  Wounds and Injuries (3)  ·  Anxiety Disorders (2)  ·  Bipolar Disorder (2)  ·  Brain Injuries, Traumatic (2)  ·  COVID-19 (2)  ·  Chronic Pain (2)  ·  Combat Disorders (2)  ·  Depressive Disorder, Major (2)  ·  Marijuana Abuse (2)  ·  Mental Disorders (2)

Broader conditions

Stress Disorders, Traumatic (56)  ·  Mental Disorders (55)  ·  Trauma and Stressor Related Disorders (54)  ·  Chemically-Induced Disorders (11)  ·  Substance-Related Disorders (10)  ·  Behavior (9)  ·  Behavioral Symptoms (7)  ·  Alcohol-Related Disorders (6)  ·  Nervous System Diseases (4)  ·  Pathological Conditions, Signs and Symptoms (4)  ·  Brain Diseases (3)  ·  Brain Injuries (3)  ·  Central Nervous System Diseases (3)  ·  Craniocerebral Trauma (3)  ·  Mood Disorders (3)

Interventions

N-Methyl-3,4-methylenedioxyamphetamine (7)  ·  Cannabidiol (5)  ·  Psilocybin (5)  ·  Ketamine (3)  ·  Propranolol (3)  ·  methylone (3)  ·  Dronabinol (2)  ·  Pregnanolone (2)  ·  SBE4-beta-cyclodextrin (2)  ·  Sodium Chloride (2)  ·  nabiximols (2)  ·  Buprenorphine (1)  ·  Dextroamphetamine (1)  ·  Levodopa (1)  ·  Medical Marijuana (1)

Sponsors

Global Coalition for Adaptive Research (5)  ·  NYU Langone Health (3)  ·  Pharmacotherapies for Alcohol and Substance Use Disorders Alliance (3)  ·  Transcend Therapeutics (3)  ·  Remedy (2)  ·  Sunstone Medical (2)  ·  Wayne State University (2)  ·  Alto Neuroscience (1)  ·  Anthony P King (1)  ·  Boston University (1)  ·  COMPASS Pathways (1)  ·  Carolina L Haass-Koffler (1)  ·  Douglas Mental Health University Institute (1)  ·  Duke University (1)  ·  Emory University (1)

Countries

United States (45)  ·  Canada (5)  ·  United Kingdom (4)  ·  Ireland (2)  ·  Israel (2)  ·  Australia (1)  ·  Brazil (1)  ·  France (1)

Top investigators

Anne Wagner, PhD (2)  ·  Charles Marmar, MD (2)  ·  Alain Brunet, Ph.D. (1)  ·  Alison Bruni, MD (1)  ·  Ann M Rasmusson, MD (1)  ·  Carolyn Rodriguez, MD, PhD (1)  ·  Charles R Marmar, MD (1)  ·  Christopher D. Verrico, PhD (1)  ·  Craig J Bryan, PsyD (1)  ·  Dr. Ryan O Lakin, MD JD (1)  ·  Erica M. Eaton, PhD (1)  ·  Esther M Blessing, MD PhD (1)  ·  Jacques Dayan, Pr (1)  ·  James Burch (1)  ·  Jessica Maples-Keller, PhD (1)

Results publications

PMID 22921765, PMID 32609959, PMID 34387679, PMID 36154908, PMID 39262902, PMID 39719161, PMID 39823496, PMID 40883964, PMID 41173838, PMID 41497513, PMID 41706459, PMID 41981270, PMID 42460632

NIH funding

R01MH122867 (2), P01AA027057 (1), R33MH108753 (1), R44MH136888 (1), U54DA037842 (1)